Current Evidence on the Use of Calcitonin Gene-Related Peptide-Targeting Therapies in Children and Adolescents
Lauren Shin, Ryan Moon, Amy Gelfand · 2026
Read Current Evidence on the Use of Calcitonin Gene-Related Peptide-Targeting Therapies in Children and Adolescents by Lauren Shin, Ryan Moon, Amy Gelfand (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13669041.txt.
Description
Lauren Shin, Ryan Moon, and Amy Gelfand review, in a 2026 paper, what is known about a newer class of migraine drugs in young patients. The drugs target a signaling molecule called CGRP. They have been used to prevent migraine in adults since 2018. Evidence in children and teenagers is only now arriving.
One randomized trial, of the drug fremanezumab in patients aged 6 to 17, found it worked as prevention for episodic migraine. A handful of real-world studies report use in patients under 18 as well. Trials of the other drugs in the class are still running. The authors conclude the early evidence points to benefit and acceptable safety in youth. They stress that the pending trials are needed before doctors can prescribe with full confidence.
Catalog record
| CREATOR | Lauren Shin, Ryan Moon, Amy Gelfand |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |